+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 128 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a drug called B007 compared to cyclosporine in treating adults with primary membranous nephropathy, a kidney condition. This study is a multicenter, randomized, controlled, open-label trial conducted in phases II and III to better understand treatment options for this disease. Participants will be randomly assigned to receive either B007 or cyclosporin capsules. B007 is given by subcutaneous injection on days 1 and 15, while cyclosporin capsules are taken orally at a dose of 3.5 mg per kg of body weight per day. The study will observe participants over about two years to assess remission rates and monitor safety. During the trial, participants will undergo laboratory tests and assessments to track overall, complete, and partial remission rates. Researchers will also monitor any treatment-emergent adverse events or serious side effects. Participants must meet specific kidney function criteria and will be followed closely throughout the study period until its completion in late 2026.

Age: 18Years - 80YearsAll GendersPhase 2Phase 3
21 locations
A

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effectiveness and safety of zonisamide as an additional treatment for children aged 1 to 14 years with focal epilepsy, including those with secondary generalized tonic-clonic seizures. The study aims to determine whether zonisamide can reduce the frequency of epileptic seizures and improve cognitive function, while also monitoring any treatment-related side effects. This open-label, observational study focuses on patients who have not achieved adequate seizure control with one antiepileptic drug. Participants will receive zonisamide tablets orally, starting at 2 mgkgday during the first two weeks. The dose increases to 4 mgkgday in weeks 3-4 and to 6 mgkgday in weeks 5-6. After six weeks, the dose is adjusted weekly by 1 mgkgday based on the patients condition, maintaining a dose between 4 and 6 mgkgday given once or twice daily. Children weighing 50 kg or more will receive adult-equivalent dosing. During the study, participants seizure frequency and cognitive function will be assessed at baseline, week 8, and week 20. Safety will be monitored through physical exams, vital signs, weight checks, and laboratory tests including liver and kidney function and blood counts. The study will use statistical software to analyze changes in seizure frequency and safety data. The total study duration is from August 1, 2024, to July 31, 2027.

Age: 1Year - 14YearsAll GendersPhase 4
1 location
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of TQH3906 capsules, a once-daily oral medication, in adults aged 18 to 75 with moderate to severe plaque psoriasis. This multicenter, randomized, double-blind, placebo- and active-controlled Phase III trial compares TQH3906 with deucravacitinib and placebo. TQH3906 selectively inhibits TYK2, targeting inflammatory pathways involved in psoriasis, aiming to support its approval for treating this condition. Participants are randomly assigned in a 221 ratio to receive TQH3906 capsules 24 mg, deucravacitinib tablets 6 mg, or placebos matching each drug during a 16-week double-blind treatment phase. After this, all participants enter a 36-week open-label extension where they receive TQH3906 capsules alone. Following treatment, there is a 4-week safety follow-up period to monitor any lasting effects. Throughout the study, participants undergo regular assessments including the static Physicians Global Assessment sPGA and Psoriasis Area and Severity Index PASI to measure skin improvement up to 16 and 52 weeks. Additional evaluations focus on scalp, nail, and palmoplantar psoriasis, quality of life via the Dermatology Life Quality Index DLQI, and drug levels in the body. Safety is closely monitored during and after the treatment periods to gather comprehensive data over a year.

Age: 18Years - 75YearsAll GendersPhase 3
45 locations
E

Actively Recruiting

Researchers are evaluating a home-based multicomponent exercise program guided by the Fogg Behavior Model designed for older adults with osteosarcopenia and frailty. This study aims to determine whether this exercise intervention can improve physical function and reduce frailty compared to routine health education. Participants will be randomly divided into two groups to assess differences in frailty status, muscle strength, physical function, bone mineral density, and quality of life. The intervention group will follow a 6-month exercise program including resistance training, balance exercises, and aerobic activities, delivered in three stages motivation and assessment weeks 1-2, personalized exercise prescription with progressive intensity and follow-up weeks 3-12, and habit formation with self-management support months 4-6. The control group will receive standard osteoporosis health education and nursing care without the exercise program. Participants will be evaluated at baseline, 3 months, and 6 months for changes in frailty phenotype score, handgrip strength, physical performance, muscle mass, bone density, quality of life, and incidence of falls. The study includes regular follow-up and behavior reminders to support adherence. The total participation spans 6 months with multiple assessments to monitor outcomes and safety.

Age: 60Years - 85YearsAll GendersPhase Not Applicable
2 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.

Age: 18Years +All GendersPhase 3
325 locations
S

Actively Recruiting

Researchers are conducting a real-world study to evaluate the impact of iptacopan on adult patients with paroxysmal nocturnal hemoglobinuria PNH in China. The study aims to assess treatment-related outcomes, disease management, and healthcare resource use, considering new standards for PNH care and the introduction of iptacopan. It includes patients who are either new to complement inhibitor therapy or those stable on C5 complement inhibitors like eculizumab. The study involves two patient groups one with PNH patients never treated with complement inhibitors who are starting iptacopan, and another with patients stable on C5 complement inhibitors who will switch to iptacopan after its approval in China. Treatments are oral capsules of LNP023 iptacopan, and patients must start iptacopan within 60 days of consenting. Participants must have documented vaccinations against Neisseria meningitidis and Streptococcus pneumoniae before starting treatment. Participants will be followed for at least 12 months, with assessments including hemoglobin levels, lactate dehydrogenase LDH, absolute reticulocyte count ARC, bilirubin, PNH clone size, and signs or symptoms related to PNH. Researchers will monitor treatment effects, adverse events, medication use, transfusions, and healthcare visits. Patient fatigue and work productivity will be evaluated using specific questionnaires, with data collected at baseline and regular intervals to understand iptacopans real-world impact on disease and quality of life.

Age: 18Years - 80YearsAll Genders
14 locations
M

Actively Recruiting

Researchers are conducting a multicenter, non-interventional, descriptive study to collect and analyze tumor samples from patients with various solid tumors, including non-small cell lung cancer NSCLC, gynecological cancers, biliary tract cancer BTC, and urothelial carcinoma UC. The study aims to assess the agreement between different laboratory tests for HER2 protein expression using immunohistochemistry IHC in Chinese pan-tumor patients. This research includes about 2100 patients diagnosed between January 2023 and September 2025 across 12 sites. The study has two phases enrollment and assessment. During enrollment, retrospective collection of tumor samples occurs, and HER2 status is tested locally using the Roche 4B5 assay. A committee reviews these results. In the assessment phase, 320 patients are selected to represent different HER2 expression levels across the tumor types. Tissue samples are sectioned and tested by multiple assays at central laboratories, and digital images of some slides are interpreted by 36 trained pathologists to evaluate consistency between tests and interpretations. Participants contribute by providing archived tumor tissue samples with sufficient slides for HER2 testing. The study evaluates the agreement between different HER2 testing assays and the consistency among pathologists interpreting these results. Researchers measure various concordance outcomes over approximately six months, including positive and negative percent agreements and inter-observer agreement. The study does not involve any treatment, and participant involvement mainly consists of sample provision and data collection from existing records.

All AgesAll Genders
14 locations
R

Actively Recruiting

Researchers are evaluating the use of robot-assisted stereotactic puncture surgery compared to conventional medical treatment for patients with brainstem hemorrhage. The study aims to create a multi-center clinical database, assess the effects of this minimally invasive surgery on survival and neurological outcomes, and improve the robotic surgical system with artificial intelligence for better planning and prediction. Participants are randomly assigned to either receive robot-assisted stereotactic minimally invasive surgery for brainstem hematoma puncture or conventional conservative medical management. The surgical procedure uses AI-based robotic navigation to plan and perform precise puncture and aspiration of the hematoma, with individualized surgical approaches based on imaging. The control group receives standard medical care that includes oxygen therapy, blood pressure control, sedation, and other supportive treatments. During the study, participants will be monitored for survival at 60 days, neurological function and recovery using various scales at 60 days and 6 months, quality of life, cognitive function, and hospital and ICU stay lengths. Imaging will assess hematoma clearance in the first week after surgery, and complications such as pneumonia or seizures will be tracked within 14 days. The study will last until June 2028, with ongoing evaluations to understand safety and efficacy of the robotic surgery approach.

Age: 18Years +All GendersPhase Not Applicable
15 locations
E

Actively Recruiting

Researchers are evaluating the drug WS016 to treat hyperkalemia, a condition characterized by high potassium levels in the blood. This open-label Phase 3 clinical trial includes two phases a corrective phase aiming to reduce potassium levels within 24 to 72 hours, followed by a maintenance phase to keep potassium levels normal over a 12-month period in participants who meet specific criteria after the first phase. Participants first receive oral doses of WS016 12 grams three times daily during the corrective phase. Those whose potassium levels normalize enter the maintenance phase, receiving WS016 once daily at 12 grams, with dose adjustments based on potassium levels over the following 12 months. This study evaluates the long-term safety and effectiveness of WS016 in maintaining normal potassium levels. Throughout the study, participants undergo regular blood tests to monitor potassium levels and safety assessments during both phases. Researchers measure the percentage of participants maintaining potassium at or below 5.0 mmolL during the maintenance phase. Adverse events and changes in potassium are tracked closely. The total participation may last over a year, including both treatment phases and follow-up assessments.

Age: 18Years +All GendersPhase 3
50 locations
R

Actively Recruiting

Researchers are evaluating whether the combination of pelabresib and ruxolitinib improves clinical outcomes compared to ruxolitinib alone in adults with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have not previously received Janus kinase inhibitor therapy. This phase 3 trial aims to assess treatment effects on spleen size and symptom scores using a randomized, double-blind design. Participants receive pelabresib or placebo orally once daily for 14 days in each 21-day cycle alongside continuous twice-daily oral ruxolitinib during the treatment period. The treatment continues until unacceptable side effects, disease progression, or withdrawal. The study includes a screening phase, a safety follow-up lasting about 30 days after last dose, an efficacy follow-up every 12 weeks for those without disease progression, and a survival follow-up with remote visits every 12 weeks for participants who progress or start new therapies. During the study, participants undergo regular assessments including spleen imaging by CT or MRI, laboratory tests, bone marrow biopsies, and symptom questionnaires. Researchers measure spleen response and symptom score changes at 24 weeks and continue monitoring multiple outcomes such as survival, anemia, and quality of life for up to three years. Safety is closely followed during and after treatment to observe any adverse events or late effects.

Age: 18Years +All GendersPhase 3
163 locations

1-10 of 128

1